Ipsen (LTS:0MH6) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0MH6 Ipsen SA LTS:0MH6
93 GF Score
Price €157.40
GF Value €141.95
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ipsen Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0MH6
93GF Score
Ipsen SA LTS:0MH6
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (LTS:0MH6) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €157.40 is trading 10.9% above its estimated GF Value™ of €141.95. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for LTS:0MH6:

  • Interest Received:
  • GF Value™: €141.95 vs. price of €157.40 (10.9% above fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the LTS:0MH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
93GF Score

Get the complete analysis for LTS:0MH6

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€157.40
Price
€141.95
GF Value